IN2014MU00495A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00495A
IN2014MU00495A IN495MU2014A IN2014MU00495A IN 2014MU00495 A IN2014MU00495 A IN 2014MU00495A IN 495MU2014 A IN495MU2014 A IN 495MU2014A IN 2014MU00495 A IN2014MU00495 A IN 2014MU00495A
Authority
IN
India
Prior art keywords
pharmaceutical compositions
abstract
cancer
preparing
treatment
Prior art date
Application number
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to ZA2015/00995A priority Critical patent/ZA201500995B/en
Priority to PCT/GB2015/050384 priority patent/WO2015121649A1/en
Priority to IN495MU2014 priority patent/IN2014MU00495A/en
Publication of IN2014MU00495A publication Critical patent/IN2014MU00495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ABSTRACT: The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor, a process for preparing such pharmaceutical compositions and use of the said pharmaceutical compositions for the treatment of cancer more specifically melanoma.
IN495MU2014 2014-02-12 2015-02-12 IN2014MU00495A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ZA2015/00995A ZA201500995B (en) 2014-02-12 2015-02-12 Low dose pharmaceutical composition
PCT/GB2015/050384 WO2015121649A1 (en) 2014-02-12 2015-02-12 Pharmaceutical composition comprising vemurafenib
IN495MU2014 IN2014MU00495A (en) 2014-02-12 2015-02-12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN495MU2014 IN2014MU00495A (en) 2014-02-12 2015-02-12

Publications (1)

Publication Number Publication Date
IN2014MU00495A true IN2014MU00495A (en) 2015-09-25

Family

ID=52544516

Family Applications (1)

Application Number Title Priority Date Filing Date
IN495MU2014 IN2014MU00495A (en) 2014-02-12 2015-02-12

Country Status (3)

Country Link
IN (1) IN2014MU00495A (en)
WO (1) WO2015121649A1 (en)
ZA (1) ZA201500995B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291089B (en) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death
US11504333B2 (en) * 2017-07-05 2022-11-22 Novartis Ag Pharmaceutical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552386T3 (en) * 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Propane-1-sulfonic acid {3- [5- (4-chloro-phenyl) -1H-pyrrole [2,3-b] pyridin-3-carbonyl] -2,4-difluoro-phenyl} -amide compositions and uses thereof
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
ZA201500995B (en) 2015-12-23
WO2015121649A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX2023008693A (en) Modulatory polynucleotides.
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2020003702A (en) Cyclopropylamines as lsd1 inhibitors.
MX2018008052A (en) Lsd1 inhibitors.
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
MX2018007421A (en) Tank-binding kinase inhibitor compounds.
MX2016015862A (en) Tank-binding kinase inhibitor compounds.
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2016010216A (en) Solid pharmaceutical compositions of androgen receptor antagonists.
IN2014MU00303A (en)
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
IN2014CH00840A (en)
IN2014MU00916A (en)
IN2014MU00495A (en)
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
MX2017005669A (en) Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof.
EA201691620A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS